Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Medical Genetics

The Biology and Genetics of Hereditary Melanoma

At a Glance

Familial melanoma is often caused by inherited genetic mutations, most commonly in the CDKN2A, CDK4, or BAP1 genes. These mutations significantly increase the risk of skin cancer and can also raise the risk for other cancers, such as pancreatic or eye cancer, making specialized screening essential.

Understanding the biology of familial melanoma means looking at the “instruction manual” inside your cells. Normally, your body has genes that act like security guards, preventing cells from growing too fast or making mistakes. In familial melanoma, one of these security guards is born with a defect [1].

The Gatekeepers: CDKN2A and CDK4

The most common genes involved in familial melanoma are CDKN2A and CDK4. These genes control the “cell cycle,” which is the process cells use to divide and grow.

  • CDKN2A: This is the most frequently mutated gene in hereditary melanoma [2]. It produces a protein called p16 that acts as a brake on cell division. When this gene is mutated, the brake fails, and cells can begin to multiply uncontrollably [3][4].
  • CDK4: This gene works in the same biological pathway as CDKN2A. A mutation here makes the cell “engine” stay on all the time, pushing the cell to divide even when it shouldn’t [5][1].

The BAP1 Syndrome

The BAP1 gene is unique because it is involved in “deubiquitination”—a process that helps the cell recycle proteins and repair DNA [6]. If you have a BAP1 mutation, you may be at risk for BAP1-TPDS (Tumor Predisposition Syndrome). This syndrome is known for a specific “cluster” of cancers:

  • Uveal Melanoma: A rare melanoma that occurs inside the eye [6].
  • Mesothelioma: A cancer of the lining of the lungs or abdomen (historically linked to asbestos, but in this case, caused by genetics) [6].
  • Renal Cell Carcinoma: A type of kidney cancer [6].
  • Nerve Tumors: Emerging research also links BAP1 to high-grade brain and spinal meningiomas [7].

Telomeres and Pigment: POT1, TERT, and MITF

Other genes focus on different parts of the cell’s survival:

  • POT1 and TERT: These genes manage telomeres, which are the protective caps on the ends of your DNA (like the plastic tips on shoelaces). Mutations in these genes allow cells to live much longer than they should, giving them more time to turn into cancer [8]. These genes, especially POT1, are also associated with an increased risk for gliomas (a type of brain tumor) [8].
  • MITF: This gene helps control the development of melanocytes (the cells that make pigment). A specific variant (p.E318K) is an “intermediate” risk factor, meaning it increases the chance of both melanoma and many atypical moles [9].

Understanding Penetrance

A key concept in genetics is penetrance. This is the probability that a person with a specific gene mutation will actually develop the disease.

  • High Penetrance: Genes like CDKN2A are often high-penetrance, meaning a large percentage of people with the mutation will develop melanoma during their lifetime [10].
  • Incomplete Penetrance: Even with a high-risk gene, not everyone gets cancer. This happens because other factors—like your environment (UV exposure) or “modifier genes” (like the MC1R gene that causes red hair)—can turn the risk up or down [11][12].

Extracutaneous Risks

“Extracutaneous” means “outside the skin.” It is vital to know that some melanoma genes affect other organs:

  • Pancreatic Cancer: People with a CDKN2A mutation have a significantly higher risk of pancreatic cancer, with a lifetime risk estimated between 5% and 24% [13][14]. Because of this, specialized screening with MRI or endoscopic ultrasound is often recommended [13][15].
  • Other Risks: Some studies suggest CDKN2A may also be linked to higher risks of tobacco-related cancers (like lung or oral cancer) and certain nervous system tumors [4][16].
Gene Primary Risk Common Extracutaneous Risks
CDKN2A Skin Melanoma Pancreas, Lung, Brain [4]
BAP1 Skin Melanoma Eye (Uveal), Kidney, Mesothelioma, Meningioma [6][7]
CDK4 Skin Melanoma Rare reports of other tumors [1]
POT1/TERT Skin Melanoma Glioma (Brain) [8]

Knowing your specific gene helps your medical team look beyond your skin to keep your whole body safe.

Common questions in this guide

What are the most common gene mutations in familial melanoma?
The most frequently mutated genes in hereditary melanoma are CDKN2A and CDK4. These genes normally help control cell growth, but when mutated, they act like a broken brake pedal, allowing cells to divide uncontrollably.
Does having a familial melanoma mutation increase my risk for other cancers?
Yes, certain melanoma genes can increase your risk of developing cancers outside the skin. For example, a CDKN2A mutation increases the risk of pancreatic cancer, while a BAP1 mutation is linked to eye melanoma, kidney cancer, and mesothelioma.
What does incomplete penetrance mean for my cancer risk?
Incomplete penetrance means that even if you inherit a high-risk melanoma gene, you may never actually develop the disease. Your overall risk is also influenced by other factors, such as UV exposure and your natural skin type.
What is BAP1 Tumor Predisposition Syndrome?
BAP1-TPDS is an inherited condition caused by a mutation in the BAP1 gene. It increases a person's risk for a specific cluster of cancers, including uveal (eye) melanoma, mesothelioma, renal cell carcinoma, and certain nerve tumors.
Do I need special screening if my family has a CDKN2A mutation?
Because CDKN2A mutations carry a significantly higher lifetime risk of pancreatic cancer, specialized screening is often recommended. This typically involves regular imaging tests like MRIs or endoscopic ultrasounds to monitor the pancreas.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific gene mutation was found in my family, and is it considered high or moderate penetrance?
  2. 2.How does my CDKN2A mutation status change the screening schedule for my pancreas?
  3. 3.Since BAP1 is associated with eye melanoma, should I be seeing an ocular oncologist or just a regular eye doctor?
  4. 4.How do my other traits, like my skin type or 'red hair genes' (MC1R), interact with my family's mutation?
  5. 5.Are there specific 'BAP1-related' skin bumps I should be looking for that are different from typical moles?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.

    Ming Z, Lim SY, Rizos H

    Biomolecules 2020; (10(10)) doi:10.3390/biom10101447.

    PMID: 33076392
  2. 2

    Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report.

    Kiyozumi Y, Matsubayashi H, Todaka A, et al.

    Hereditary cancer in clinical practice 2024; (22(1)):11 doi:10.1186/s13053-024-00283-7.

    PMID: 38961426
  3. 3

    Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.

    Boşoteanu LA, Gheorghe E, Aşchie M, et al.

    Medicine 2023; (102(51)):e36756 doi:10.1097/MD.0000000000036756.

    PMID: 38134090
  4. 4

    Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports.

    van der Wilk BJ, Noordman BJ, Atmodimedjo PN, et al.

    European journal of medical genetics 2020; (63(3)):103840 doi:10.1016/j.ejmg.2020.103840.

    PMID: 31923587
  5. 5

    Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.

    Potjer TP, Bollen S, Grimbergen AJEM, et al.

    International journal of cancer 2019; (144(10)):2453-2464 doi:10.1002/ijc.31984.

    PMID: 30414346
  6. 6

    Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma.

    Masoomian B, Shields JA, Shields CL

    Journal of current ophthalmology 2018; (30(2)):102-109 doi:10.1016/j.joco.2018.02.005.

    PMID: 29988936
  7. 7

    High frequency and unique subtypes of meningioma in patients with BAP1 tumor predisposition syndrome.

    Ramsey KA, Byrne L, Taylor OB, et al.

    Journal of neuro-oncology 2026; (176(3)):207.

    PMID: 41670784
  8. 8

    POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.

    Potrony M, Puig-Butille JA, Ribera-Sola M, et al.

    The British journal of dermatology 2019; (181(1)):105-113 doi:10.1111/bjd.17443.

    PMID: 30451293
  9. 9

    Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients.

    Ciccarese G, Dalmasso B, Bruno W, et al.

    Journal of translational medicine 2020; (18(1)):78 doi:10.1186/s12967-020-02253-8.

    PMID: 32054529
  10. 10

    Cell Senescence and the Genetics of Melanoma Development.

    Constantinou SM, Bennett DC

    Genes, chromosomes & cancer 2024; (63(10)):e23273 doi:10.1002/gcc.23273.

    PMID: 39422311
  11. 11

    Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.

    Soares de Sá BC, Moredo LF, Torrezan GT, et al.

    International journal of molecular sciences 2023; (24(21)) doi:10.3390/ijms242115830.

    PMID: 37958811
  12. 12

    Familial Melanoma Phenotype With Xeroderma Pigmentosum Group C (XP-C) Genotype - The Putative Role of MC1R Polymorphism as Modifier.

    Leidenz FAB, Bittencourt FV, Braga WG, et al.

    Dermatology practical & conceptual 2024; (14(1)) doi:10.5826/dpc.1401a50.

    PMID: 38364385
  13. 13

    Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants.

    Pauley K, Khan A, Kohlmann W, Jeter J

    Frontiers in oncology 2022; (12()):837057 doi:10.3389/fonc.2022.837057.

    PMID: 35372037
  14. 14

    Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants.

    Overbeek KA, Rodríguez-Girondo MD, Wagner A, et al.

    Journal of medical genetics 2021; (58(4)):264-269 doi:10.1136/jmedgenet-2019-106562.

    PMID: 32482799
  15. 15

    Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome.

    Matsubayashi H, Morizane C, Kanai M, et al.

    International journal of clinical oncology 2025; doi:10.1007/s10147-025-02905-z.

    PMID: 41118024
  16. 16

    Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.

    Jeong AR, Forbes K, Orosco RK, Cohen EEW

    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 2022; (51(1)):5 doi:10.1186/s40463-022-00556-y.

    PMID: 35123577

This page provides educational information about the genetics of familial melanoma. It does not replace professional medical advice. Always consult a genetic counselor or oncologist about your personal risk and screening needs.

Get notified when new evidence is published on Familial melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.